Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMEXMYK)

Drug Name
Alpelisib Drug Info
Synonyms
alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
Cross-matching ID
PubChem CID
56649450
ChEBI ID
CHEMBL2396661
CAS Number
CAS 1217486-61-7
TTD Drug ID
D0W7HE
INTEDE Drug ID
DR0074
ACDINA Drug ID
D00827

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 1.99 2.05e-2 34/36 (94.44%) PCNA;MCM2;MCM4;...
Cell cycle 1.91 1.36e-2 110/124 (88.71%) MYC;CCNB2;WEE1;...
Nitrogen metabolism 1.86 1.36e-2 16/17 (94.12%) GLUL;GLUD1;CPS1;...
TGF-beta signaling pathway 1.76 4.43e-2 81/94 (86.17%) MYC;DCN;FST;...
alpha-Linolenic acid metabolism -1.61 4.98e-2 17/25 (68%) PLA2G5;PLA2G4C;PLAAT3;...
Prion disease -1.64 4.03e-2 209/273 (76.56%) ATP5MC3;RAC2;ATP5F1E;...
Fc epsilon RI signaling pathway -1.65 3.93e-2 57/68 (83.82%) MAP2K4;INPP5D;PLCG1;...
Yersinia infection -1.65 4.03e-2 120/137 (87.59%) CD4;PLCG1;AKT1;...
Allograft rejection -1.65 4.19e-2 32/38 (84.21%) HLA-C;TNF;FAS;...
Toxoplasmosis -1.68 3.17e-2 103/112 (91.96%) HLA-DPB1;MAP2K6;IL10;...
Synaptic vesicle cycle -1.69 3.25e-2 63/78 (80.77%) ATP6V0D1;ATP6V0B;AP2M1;...
SNARE interactions in vesicular transport -1.69 3.21e-2 19/33 (57.58%) STX3;GOSR2;STX18;...
Pertussis -1.70 3.24e-2 64/76 (84.21%) CASP1;IL10;IRAK1;...
Osteoclast differentiation -1.71 2.92e-2 117/127 (92.13%) TNFSF11;AKT1;GRB2;...
TNF signaling pathway -1.72 2.93e-2 103/112 (91.96%) LTA;AKT1;CCL20;...
Epstein-Barr virus infection -1.74 2.49e-2 189/202 (93.56%) HLA-DPB1;MAP2K6;PSMD6;...
Autoimmune thyroid disease -1.76 2.08e-2 46/53 (86.79%) HLA-DPB1;IL10;TPO;...
Cell adhesion molecules -1.77 1.87e-2 118/148 (79.73%) ITGAL;NRXN3;NECTIN1;...
Graft-versus-host disease -1.78 1.99e-2 32/42 (76.19%) IL1B;HLA-C;TNF;...
IL-17 signaling pathway -1.79 1.94e-2 84/94 (89.36%) CCL20;FADD;PTGS2;...
Lysosome -1.83 1.15e-2 115/128 (89.84%) ABCB9;ARSA;PPT1;...
Biosynthesis of unsaturated fatty acids -1.84 1.13e-2 21/27 (77.78%) ELOVL1;HSD17B12;HACD1;...
Toll-like receptor signaling pathway -1.87 7.42e-3 94/104 (90.38%) TOLLIP;MAP2K6;IRAK1;...
Fructose and mannose metabolism -1.90 6.80e-3 30/33 (90.91%) HK1;HK3;PFKFB1;...
Pentose phosphate pathway -1.92 6.04e-3 25/30 (83.33%) TKTL1;TALDO1;PFKP;...
Phagosome -1.97 5.10e-3 118/152 (77.63%) DYNC1LI1;COMP;ITGB3;...
Tuberculosis -2.01 0.00e+0 159/180 (88.33%) NOD2;ATP6V0D1;ATP6V0B;...
Antigen processing and presentation -2.06 0.00e+0 60/78 (76.92%) HLA-DPB1;CTSL;HSPA5;...
Protein processing in endoplasmic reticulum -2.17 0.00e+0 127/171 (74.27%) SEC13;HSPA5;MOGS;...
Steroid biosynthesis -2.17 0.00e+0 19/20 (95%) FDFT1;EBP;NSDHL;...
Rheumatoid arthritis -2.21 0.00e+0 78/93 (83.87%) CD80;CXCL6;TNFSF11;...
Proteasome -2.22 0.00e+0 44/46 (95.65%) PSMB7;PSMD8;PSMA1;...
Legionellosis -2.26 0.00e+0 51/57 (89.47%) HSPD1;HSPA8;IL1B;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.25uM 6H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H